28 March 2024
28 March 2024
The FDA decision was based on safety and efficacy data from the INNO₂VATE programme.
The approval was based on the results of a 32-week pharmacokinetic bridging clinical trial.
Blackstone is entitled to receive milestone and royalty payments on 'flu products resulting from the deal.
Cardiovascular device maker Shockwave has a marketed C²⁺ IVL catheter for the treatment of severely calcified coronary artery disease.
Pegozafermin is currently in a Phase III trial, with another on the way soon.
The market for multiple sclerosis therapies is expected to be worth over $41bn by 2030, according to GlobalData.
The approval was based on data from the CAPItello-291 Phase III clinical trial in 708 adult patients.
Ubiquigent will deploy its DUB-focused platform to advance Debiopharm’s USP1 inhibitor to the clinic.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
